Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria.[L11830] It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance.[L11830] In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.
Sulfamethoxazole and Trimethoprim (Double Strength)
SulfatrimTM Pediatric Suspension
Sulfamethoxazole and Trimethoprim Injection, BP
Apo-sulfatrim Oral Suspension
Sulfatrim Pediatric
Teva-trimel DS
Bactrim Roche Suspension Paediatric
Sulfamethoxazole and Trimethoprim for Injection, USP
Sulfatrim DS
Riva-sep DS
Septra Grape
Septra Injection
SULFAMETHOXAZOLE and TRIMETHOPRIM
Sulfatrim
Sulfamethoxazole and Trimethoprim Double Strength
Roubac Tab 160/800
Septra DS
Sulfamethoxazole and Trimethoprim DS
Sulfamethoxazole and Trimethoprim
Nu-cotrimox-DS Tab 800/160mg
Septra Pediatric Suspension
Trisulfa DS Tab
Protrin Tab
Sulfamethoxazole Tab 500mg
Septra DS Tablets
Trisulfa Tab
Septra
sulfamethoxazole-trimethoprim (SMZ)
Trisulfa S Suspension
Bactrim
Sulfameth/Trimeth-DS
Sulfamethox-TMP DS
Bactrim DS Roche Tab
SULFAMETHOXAZOLE AND TRIMETHOPRIM double strength
Teva-trimel
Indication
Sulfamethoxazole is indicated in combination with trimethoprim, in various formulations, for the following infections caused by bacteria with documented susceptibility: urinary tract infections, acute otitis media in pediatric patients (when clinically indicated), acute exacerbations of chronic bronchitis in adults, enteritis caused by susceptible _Shigella_, prophylaxis and treatment of _Pneumocystis jiroveci_ pneumonia, and travelers' diarrhea caused by enterotoxigenic _E. coli_.[L11830,L11863] In Canada, additional indications include the adjunctive treatment of cholera, treatment of bacillary dysentery, nocardiosis, and second-line treatment of brucellosis in combination with [gentamicin] or [rifampicin].[L11851]
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
